Table 1 Clinical and pathological characteristics, hormonal receptor status, stages, and adjuvant chemotherapy of all patients grouped as <35 years (group 1), between 35–50 years (group 2) and >50 years (group 3).
From: Effects of young age at presentation on survival in breast cancer
Variable | Group1 = <35 | Group2 = 35–49 | Group3 = >50 | Total | P value |
|---|---|---|---|---|---|
Tumor size<2 cm | 16 (15.7%) | 95 (20.0%) | 115 (18.8%) | 1191 | 0.877 |
Tumor 2–5 cm | 70 (68.6%) | 315 (66.1%) | 407 (66.4%) | ||
> 5 cm | 16 (15.7%) | 66 (13.9%) | 91 (14.8%) | ||
Lymph Node Positive | 70 (68.6%) | 317 (66.7%) | 378 (61.6 %) | 1191 | 0.131 |
Positive hormone Receptors (estrogen and/or progesterone) | 73 (71.6%) | 321 (67.6%) | 482 (78.5%) | 876/1191 | <0.001 |
Grade I | 5 (4.9%) | 49 (10.3%) | 79 (12.9%) | 1191 | 0.019 |
Grade II | 47 (46.1%) | 226 (47.6%) | 315 (51.3%) | ||
Grade III | 50 (49%) | 200 (42.1%) | 220 (35.8%) | ||
Stage I | 12 (11.2%) | 74 (14.8%) | 96 (14.6%) | 182 (14.4%) | 0.619 |
Stage II | 63 (58.9%) | 305 (61.1%) | 389 (59.1%) | 757 (59.9%) | |
Stage III | 27 (25.2%) | 96 (19.2%) | 129 (19.7%) | 252 (20.0%) | |
Stage IV** | 5 (4.7%) | 24 (4.8%) | 44 (6.6%) | 72 (5.7%) | |
Adjuvant Chemotherapy | 78 (76.5%) | 346 (72.8%) | 326 (53.1%) | 750/1191 | <0.001 |
Adjuvant Anthracycline* | 42 (56.0%) | 228 (68.3%) | 163 (50.6%) | 443/731 | <0.001 |
Development of metastasis | 33 (32.4%) | 109 (22.9%) | 140 (22.8%) | 282/1191 | 0.098 |